Pyxis Oncology, Inc. (PYXS)
Total Valuation
Pyxis Oncology has a market cap or net worth of $66.93 million. The enterprise value is -$45.89 million.
Market Cap | 66.93M |
Enterprise Value | -45.89M |
Important Dates
The last earnings date was Tuesday, November 7, 2023, after market close.
Earnings Date | Nov 7, 2023 |
Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 44.32 million shares outstanding. The number of shares has increased by 26.94% in one year.
Shares Outstanding | 44.32M |
Shares Change (YoY) | +26.94% |
Shares Change (QoQ) | +7.67% |
Owned by Insiders (%) | 30.93% |
Owned by Institutions (%) | 26.24% |
Float | 29.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.49 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.91, with a Debt / Equity ratio of 0.16.
Current Ratio | 4.91 |
Quick Ratio | n/a |
Debt / Equity | 0.16 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.30% and return on invested capital (ROIC) is -64.18%.
Return on Equity (ROE) | -63.30% |
Return on Assets (ROA) | -49.90% |
Return on Capital (ROIC) | -64.18% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.41M |
Employee Count | 67 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.10% in the last 52 weeks. The beta is 1.12, so Pyxis Oncology's price volatility has been higher than the market average.
Beta (1Y) | 1.12 |
52-Week Price Change | +3.10% |
50-Day Moving Average | 1.72 |
200-Day Moving Average | 2.47 |
Relative Strength Index (RSI) | 41.67 |
Average Volume (30 Days) | 124,473 |
Short Selling Information
The latest short interest is 801,069, so 1.81% of the outstanding shares have been sold short.
Short Interest | 801,069 |
Short Previous Month | 792,474 |
Short % of Shares Out | 1.81% |
Short % of Float | 2.70% |
Short Ratio (days to cover) | 9.29 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -102.40M |
Pretax Income | -94.29M |
Net Income | -94.29M |
EBITDA | -92.12M |
EBIT | -94.29M |
Earnings Per Share (EPS) | -$2.55 |
Balance Sheet
The company has $134.44 million in cash and $21.62 million in debt, giving a net cash position of $112.82 million or $2.55 per share.
Cash & Cash Equivalents | 134.44M |
Total Debt | 21.62M |
Net Cash | 112.82M |
Net Cash Per Share | $2.55 |
Equity / Book Value | 137.95M |
Book Value Per Share | 3.11 |
Working Capital | 110.76M |
Cash Flow
In the last 12 months, operating cash flow was -$72.84 million and capital expenditures -$8.58 million, giving a free cash flow of -$81.43 million.
Operating Cash Flow | -72.84M |
Capital Expenditures | -8.58M |
Free Cash Flow | -81.43M |
FCF Per Share | -$1.97 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Earnings Yield | -140.89% |
FCF Yield | -121.66% |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Buyback Yield | -26.94% |
Shareholder Yield | -26.94% |
Analyst Forecast
The average price target for Pyxis Oncology is $12.00, which is 694.70% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $12.00 |
Price Target Difference | 694.70% |
Analyst Consensus | Strong Buy |
Analyst Count | 3 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -5.83% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |